Navigation Links
Boston University biomedical engineers find chink in bacteria's armor
Date:9/6/2007

Biomedical researchers at Boston Universitys College of Engineering may have discovered the path toward developing better drugs capable of defeating so-called superbugs, bacteria that have developed resistance to common antibiotics. The researchers have discovered a previously unknown chain of events occurring in bacteria that opens to door to new avenues of research.

Currently, three classes of bactericidal antibiotics are used to target different bacterial functions: inhibiting DNA replication; blocking protein-building; or halting construction of cell walls. Research from the laboratory of Professor James Collins found the three classes more alike than anyone realized, and the commonalities may be the bugs downfall.

Collins and colleagues article, A Common Mechanism of Cellular Death Induced by Bactericidal Antibiotics, appears in the September 7 issue of Cell.

The researchers discovered a common process, or pathway, that was triggered by all three types of antibiotics. Theres an underlying pathway beyond the drug interacting with the target, said graduate student and lead author Michael Kohanski, and the endpoint of this pathway is excessive free radical production.

Free radicals -- such as hydroxyl or superoxide radicals -- are molecules that carry a free, or unpaired, electron like a weapon. Theyll damage DNA, proteins, lipids in the membrane, pretty much anything. Theyre equal opportunity damagers, said Kohanski.

This hidden pathway and resultant free radical overload appears to help current antibiotics do their job, but is not always enough to kill all bacteria by itself. Collins group theorizes that if this effect can be amplified, or if the cells genetic defense against it can be weakened, no bacteria could withstand its effect and the emergence of antibiotic-resistant bacteria could be limited.

Importantly, we showed that if you can inhibit or block the bacterial defense mechanisms to hydroxyl radical damage, you can potentiate or enhance the lethality of bactericidal antibiotics. This highlights the value of taking a network biology approach to antibiotics and provides a framework for creating new classes of drugs, said Collins.

What we think is happening is the cell is getting a signal that says, Theres something wrong with our energy production system and we need to make more energy. But, theres really nothing wrong. The cell becomes confused, turns on too many processes at once and its overwhelmed, said Kohanski.

Previous work by Kohanski and co-lead author Dan Dwyer, a postdoctoral researcher in Collins lab, revealed the first hints that this underlying pathway exists. In studying bacterial response to a quinolone, an antibiotic that inhibits DNA replication, they noted a surprising change in genes responsible for energy production and iron uptake.

In the current study, the researchers used DNA microarray studies to see if all three classes of bactericidal antibiotics triggered this process. Across the board, they noted increased gene activity along the intracellular assembly lines that make energy for the bacterial cell, just as in the earlier study. They began to deduce the details of the new pathway.

Cells produce free superoxide radicals naturally in oxygen-rich environments, but when they unnecessarily ramp up energy production to a frantic pace such as when triggered by antibiotics more radicals get churned out than the cells safety measures can mop up. The superoxide radicals then pull iron from other components of the cell, and this iron rapidly stimulates production of toxic levels of hydroxyl radicals.

Its really amazing that despite the diversity of targets, you have everything funneling into this common pathway, where theres a global meltdown occurring, said Dwyer. Theres almost no way for the cell to recover from this. It shows you how potent these molecules are to damaging and killing the cell.

In addition to potentially making bacteria more vulnerable to current drugs, this finding may revitalize development of antibiotic drugs sidelined because of narrow differences between therapeutic and toxic doses. Such drugs might re-enter the pipeline, if this free-radical producing pathway is exploited to lower the therapeutic dose, making formerly dangerous drugs safer.


'/>"/>

Contact: Mike Seele
mseele@bu.edu
617-353-9766
Boston University
Source:Eurekalert

Related biology news :

1. Boston University biomedical engineers win major grant for pursuit of the $1,000 Genome
2. University of Manchester makes made-to-measure skin and bones a reality using inkjet printers
3. New protein discovered by Hebrew University researchers
4. Next Generation Body Scanner Launched By The University Of Manchester
5. Roundup®highly lethal to amphibians, finds University of Pittsburgh researcher
6. Green catalyst destroys pesticides and munitions toxins, finds Carnegie Mellon University
7. University of Nevada, Reno research team discovers hormone that causes malaria mosquito to urinate
8. Carnegie Mellon University research reveals how cells process large genes
9. University of Delaware researchers develop cancer nanobomb
10. University of Arizona plant scientists to unravel maize genome
11. Team led by Carnegie Mellon University scientist finds first evidence of a living memory trace
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016  Global demand for ... percent through 2020 to $7.2 billion.  This market ... beverages, cleaning products, biofuel production, animal feed, and ... diagnostics, and biocatalysts). Food and beverages will remain ... by increasing consumption of products containing enzymes in ...
(Date:6/27/2016)... ... 2016 , ... Newly created 4Sight Medical Solutions ... healthcare market. The company's primary focus is on new product introductions, to include ... are necessary to help companies efficiently bring their products to market. , The ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology: